Panelists discuss how combination trials like VIALE-A and VIALE-C have demonstrated venetoclax’s survival benefits when added to hypomethylating agents, opening doors for numerous combination studies ...
Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...
– Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – NPM1 mutations are among the most common founder mutations in AML, occurring in ...
(A and B) Preparation process of the self-assembly of peptide, DNR prodrug, and siRNA, along with the corresponding formulation ratios. (C) DLS detection of the particle size of PDR at different ...
News-Medical.Net on MSN
New study exposes a targetable vulnerability in acute myeloid leukemia
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...
Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...
Syndax Pharmaceuticals received expanded FDA approval for Revuforj, tripling its addressable AML patient population despite a boxed safety warning. Revumenib remains the only FDA-approved menin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results